Short-term postoperative neurocognitive safety and recovery profiles of remimazolam tosilate combined with flumazenil vs. propofol in cirrhotic patients undergoing endoscopic variceal treatment: a randomized controlled trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Analysis of Short-term Neurocognitive Outcomes and Recovery in Cirrhotic Patients Undergoing Endoscopic Variceal Procedures: Remimazolam Tosilate with Flumazenil Versus Propofol in a Randomized Controlled Trial

  • By

  • Yanjie Chen

  • Xiangrong Du

  • Fu Shi

  • Na Zhu

  • September 4, 2026

Share

  • 1

    The study evaluated remimazolam tosilate with flumazenil versus propofol in cirrhotic patients undergoing endoscopic variceal procedures.

  • 2

    Primary outcomes included neurocognitive tests (NCT-A and DST) assessed preoperatively and at 6 and 24 hours postoperatively.

  • 3

    Both groups showed significant changes in neurocognitive performance, but no significant differences were found between the two anesthetic regimens.

  • 4

    Group R (remimazolam) demonstrated significantly faster recovery metrics compared to Group P (propofol) at various postoperative time points.

  • 5

    Remimazolam tosilate combined with flumazenil was associated with better recovery quality in cirrhotic patients undergoing endoscopic treatment.

Original Source(s)

Short-term postoperative neurocognitive safety and recovery profiles of remimazolam tosilate combined with flumazenil vs. propofol in cirrhotic patients undergoing endoscopic variceal treatment: a randomized controlled trial

  • by Yanjie Chen, Xiangrong Du, Fu Shi, Na Zhu

  • September 4, 2026

Related Content

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.

  • by

  • September 4, 2026

  • 3 min
SCO‑792 alleviates HFD‑aggravated chronic pancreatitis by modulating the gut–pancreas axis via the AMPK/ACC and TLR4/NF‑κB signaling pathways

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min